FDA: No More Niacin Combos
(MedPage Today) -- Agency pulls plug on niacin plus statin and niacin fenofibric acid
Purpose of review The goal of this review is to present recent models of the filtration barrier that may suggest mechanism-based treatments for proteinuric renal disease. The vast majority of renal failure occurs in diseases of glomerular proteinuria. The physiology of the filtration barrier remains incompletely understood, preventing invention of mechanism-based therapies. Research is currently dominated by molecular biology approaches to the kidney instead of engineering-based filtration and transport models. Recent findings Reexamination of two older paradigms (basement membrane and slit diaphragm) and critical ana...
Statins are the only Class I ISHLT recommendation in heart transplantation (HT) as an established therapy to reduce cardiac allograft vasculopathy (CAV) and improve survival. However, the goal LDL is not known with no formal recommendation on targets. We assessed if LDL
Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplant (LT) Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have shown to have immunomodulatory and antiinflamatory effects unrelated to their cholesterol-lowering function. We hypothesized that recipient's preoperative statin therapy is associated with decreased incidence of PGD after LT.
This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV) and related outcomes of rejection and mortality after cardiac transplant in the setting of tacrolimus as primary calcineurin inhibitor.
In this study, we analyzed myocardial gene expression profiles in cardiac allografts after donor simvastatin treatment.
Left ventricular (LV) global longitudinal strain (GLS) is a robust marker of subclinical myocardial dysfunction. Previous studies showed that as small as 2% reduction in GLS predicted major adverse event in heart transplant (HT) recipients, including cardiac allograft vasculopathy (CAV). Although low intensity statin is commonly used after HT to reduce CAV, the incremental impact of statin intensity on myocardial function is unknown.
ConclusionsStatin initiators had a lower risk of any ALI outcome compared with non-users within 18 months regardless of HIV and/or HCV status.
As yet there's no magic bullet that offers protection against coronavirus. And even though vitamin C supplements are selling in huge quantities, hard evidence on its effectiveness is lacking.
For decades, omega-3 fatty acids (O3FA) have been utilized for their cardioprotective effects. Although several prescription products are available, icosapent ethyl (IPE) is the only pure, eicosapentaneoic acid (EPA)-only, O3FA product. Initially approved by the Food and Drug Administration (FDA) to reduce triglyceride (TG) levels in patients with TG levels ≥500 mg/dL, the Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial (REDUCE-IT) demonstrated that IPE reduces cardiovascular events in patients with either established atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus pl...
ABSTRACTSeveral epidemiological studies have reported a relationship between statin treatment and increased bone mineral density (BMD) and reduced fracture risk, but the mechanism underlying the purported relationship is unclear. We used Mendelian randomization (MR) to assess whether this relationship is explained by a specific effect in response to statin use or by a general effect of lipid lowering. We utilized 400 single ‐nucleotide polymorphisms (SNPs) robustly associated with plasma lipid levels as exposure. The outcome results were obtained from a heel estimated BMD (eBMD) genomewide association study (GWAS) from t...